Aim Immunotech Inc. (AIM)
XASE:AIM
Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$1.25
>-$0.01(-4.03%)
At close: 4:00 PM EST
$1.25
>-$0.01(-4.03%)
Day’s Range― - ―
52-Week Range$0.21 - $20.33
Previous CloseN/A
Volume272.06K
Average Volume (3M)17.68M
Market Cap
$3.45M
Enterprise Value-$434.68K
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$4.57M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding14,563,515
10 Day Avg. Volume51,314,649
30 Day Avg. Volume17,677,122
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.17
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-4.62
Enterprise Value/Gross Profit3.48
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$5.75Price Target Upside360.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.47
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThirteen active clinical trials and positive Phase 2 Ampligen data create multiple potential clinical readouts that could materially improve investor confidence and valuation.
Financial RunwayRecent fundraising bolstered the balance sheet and provides cash into late-2026, supporting continued research and development without immediate capital strain.
Regulatory ProgressOngoing discussions with the FDA about pivotal study design for Ampligen suggest a clearer regulatory pathway that could enhance approval prospects if agreement is reached.
Bears Say
Listing And Governance HistoryA prior delisting from the NYSE American indicates past market or compliance instability that may continue to weigh on investor trust despite relisting.
Revenue GenerationMinimal revenue as an early-stage clinical company increases reliance on external financing and raises the risk of dilution or funding shortfalls.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $0.21 and its highest was $20.33 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $3.45M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 83 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Currently, no data Available
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 14,563,515 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
AIM Stock 12 Month Forecast
Average Price Target
$5.75
▲(360.00% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
0.20% Mutual Funds
<0.01% Other Institutional Investors
98.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---